IL-10, interleukine-10
Follow-up continued until treatment discontinuation, a switch to another drug class, occurrence of a CV or safety event, death, end of health plan enrollment or the end of the study
doi: 10.1074/jbc.272.51.31937 144 Alingh PrinsAde Jong-NagelsmitAKeijserJStrubbeJH
Notably, while initially demonstrated in patients with T2DM, recent landmark trials have shown that semaglutide also significantly reduces primary cardiovascular endpoint events (including cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in obese patients without diabetes, substantially expanding their potential cardioprotective applications
Remember the phosphocreatine I talked about a minute ago
Common early side effects include nausea, fullness, mild constipation or diarrhea, and a decreased desire to eat